One company is about to start phase 2 trials One company is about to start phase 2 trials
                                                                                                     [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor,
Biotech is one of the hottest sectors on the market.
In fact, a big part of the reason why is obesity.
Since the start of the year, Eli Lilly (LLY) jumped from about $560 to $778. Part of that was thanks to sales of its obesity drug, Zepbound which saw $175.8 million in its first month out. Even better, Eli Lilly is seeing positive results in Phase 2 drug trials for patients with NASH, or nonalcoholic steatohepatitis, which impacts about 115 million patients all around the world.
Or, look at Novo Nordisk (NVO), which jumped from about $95 to a high of $135 thanks to Wegovy obesity drug sales, too. The company even forecast another year of double-digit sales growth for this year, and expects to boost U.S. supplies of Wegovy again this year. --------------------------------------------------------------- [Wall Street Stockpicker Names #1 AI Stock of 2024](
The greatest quantitative mind on Wall Street just revealed his #1 A.I. pick, 100% free. [Click here to learn more...]( --------------------------------------------------------------- Thereâs also Viking Therapeutics (VKTX).
The company is seeing good success with its GLP-1 obesity drug trials. It already reported that its Phase 2 VENTURE trial successfully achieved is primary endpoint and all secondary endpoints. It also said patients receiving VK-2735 demonstrated weight loss after 13 weeks, rating up to 14.7% from baseline weight.
It's also about to start Phase 2 trials of its once-a-day weight loss pill. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days, as noted by CNBC.
This is just the start, though. --------------------------------------------------------------- [The 10-Minute Trader [Just One Easy Trade]](
Hugh Grossman introduces a unique "day trading" system that involves just one simple option trade taking 10 minutes a day, unlike traditional day trading involving hours glued to the screen. This fast and easy system requires opening an email, typing in the option symbol, setting the profit target, and walking away for the rest of the day. Only 87 new option traders today get to see how this new way to trade works, so better hurry. [Click here for the 10-minute simple options trading day.]( --------------------------------------------------------------- We also have to consider the obesity drug market could explode to $100 billion by 2030, says Goldman Sachs. âThe obesity market is still in its early stages,â Chris Shibutani, senior biopharmaceuticals analyst in Goldman Sachs Research, writes in the teamâs report, noting there are uncertainties around the assumptions in the teamâs model. The $100 billion forecast is ârelatively sensitive to minor tweaks to underlying drivers.â
In addition, according to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults were overweight as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016, as well. Â
At the rate weâre going, obesity will be the downfall for millions.
However, if millions of people can take a pill or get a shot to help lose weight, it could create an unbelievable multi, multi-billion-dollar opportunity. ---------------------------------------------------------------
[Potential Danger For Retirement Accounts Tied to Stocks]( Market Corrections can eat into the value of your account. This FREE Guide can help you discover ways that may assist in keeping more of your money where you want it.
[GET YOUR FREE GOLD GUIDE NOW]( --------------------------------------------------------------- [Join Daily Guru Trades!](
Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.](
Are you invested in weight loss stocks? Do you have your eye on any we might have missed? Hit "reply" to this email and let us know! "The Buck Stops Here" Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets]( Â [Unsubscribe]( Â